Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Big pharma’s interest in the therapeutic potential of modulating the body’s own bacterial ecosystem is growing, particularly with regard to the treatment of inflammatory disorders.
Although specific age-related disorders such as Alzheimer’s disease continue to be a focus of research and development investment and dealmaking activity, companies are also beginning to approach aging in a broader way.
